Key takeaways
- DSIP is a nine-amino-acid peptide first noticed for inducing delta-wave sleep in rabbits.
- The site rates its evidence 2 of 5: small, mixed human trials from the 1980s–90s and no modern randomized trials.
- Newer work is mostly in mice, and a recent review notes a lack of clinical trials.
- Missing FDA approval is normal for most peptides and doesn't show DSIP fails; it mostly shows nobody has funded the big trials.
Few peptides have a name as appealing as "delta sleep-inducing peptide." It suggests a clear job: help the brain reach the slow, deep sleep that people chase. That idea has kept DSIP in online sleep and stress conversations for decades.
The topic brief for this post described DSIP as the one peptide an FDA advisory panel voted down, by 6–7, while six others got yes votes. That vote isn't in the sources used here, so this post doesn't rely on it. Instead it looks at what the research on file shows, which may explain why DSIP is a harder case than some others.
Where DSIP came from: rabbits and slow-wave sleep
DSIP is a nonapeptide, meaning nine amino acids. According to the site's entry, it induced delta-wave sleep in early rabbit studies, which is where the name comes from.
Its mechanism is described as poorly understood. The entry says it appears to modulate stress hormones and sleep architecture. It also has a short half-life of about 7–8 minutes, which makes it hard to say how a brief presence in the body would produce lasting effects on sleep.
What the human studies look like
The site's entry rates DSIP's evidence 2 of 5: mixed, small human trials from the 1980s–90s, and no modern randomized controlled trials. The listed human areas are sleep onset and stress or withdrawal effects. That is a modest but real starting point, not a blank page.
"Mixed" matters here. Small trials that point in different directions can't settle whether a compound helps. They also can't rule it out. Older studies often used methods that today's trials have since tightened up, so they're hard to compare with modern work.
This is the same evidence level the site gives DSIP in its ranking of peptides by evidence. Level 2 sits well below compounds with large, modern trials behind them.
What newer work adds
A 2024 mouse study tested a DSIP fusion peptide, DSIP joined to a sequence meant to help it cross the blood-brain barrier, in mice made insomnic with a chemical (PCPA) 1. Going only by the abstract, the fusion peptide changed levels of neurotransmitters including serotonin, glutamate, dopamine and melatonin. The authors report it restored that balance better than DSIP alone and may enhance sleep 1.
That is interesting, especially because getting a peptide into the brain is a real puzzle. But it's a mouse model of induced insomnia, and an abstract is all we have of it here. It can't tell us what happens in people with ordinary sleep trouble.
A January 2026 review of therapeutic peptides in orthopaedics lists DSIP among "recovery-enhancing" agents thought to act on circadian and mitochondrial regulators 2. The same abstract says that although preclinical studies are promising, there is a current lack of clinical trials 2. Again, an abstract is all we have of it, and it isn't a DSIP sleep study.
Why approval status isn't the whole story
Most peptides in this space lack FDA approval. That mostly reflects money: approval follows large, expensive trials that a company has to decide to pay for. Many compounds never get them for financial reasons, and nobody has shown they don't work. Likewise, FDA status doesn't tell you a compound works.
DSIP has a few extra hurdles. It's a molecule that can be made in the lab, and a 2023 chemistry paper used DSIP as a showcase for a cleaner method of building peptides 3. That shows DSIP is easy to make, not that it helps sleep. It also breaks down within minutes and its mechanism is unclear, which makes designing a convincing trial harder. A thin, mixed record may be a fair reason for a panel to hesitate, even if the question is still open.
What people's own experience can and can't tell us
Some people use DSIP for sleep and stress and report on it, and the site's entry notes this while calling the evidence weak. People comparing notes can be a useful source of ideas about what's worth testing. Sleep is also strongly affected by expectation, season, stress and routine, so personal accounts can't separate the peptide's effect from everything else.
DSIP is also on the WADA banned list, which matters for anyone in tested sport.
The bottom line
DSIP has a charming origin story, a small and mixed human record rated 2 of 5, and some early mouse work on a modified version. What's missing is a modern, well-run human trial. Until someone funds one, its sleep effects stay an open question rather than a settled one.
If you want to see how the ratings work across peptides, the free AI connector with the evidence ratings is at mypeps.info/ai.
This is educational information, not medical advice.
Sources
- Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. — Frontiers in pharmacology, Oct 2024. https://pubmed.ncbi.nlm.nih.gov/39444618/
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, Jan 2026. https://pubmed.ncbi.nlm.nih.gov/41490200/
- Practical N-to-C peptide synthesis with minimal protecting groups. — Communications chemistry, Oct 2023. https://pubmed.ncbi.nlm.nih.gov/37884638/